IL20 and neoplasm: Chiu et al. found that an anti-IL-20 mAb inhibited tumor growth in ML-1 cell-injected mice and suppressed the expression of TNF-α, cyclin D1, and MMP-9 in mice, suggesting that an anti-IL-20 mAb has the potential to be an effective therapeutic agent for HCC [39].